Gainers

  • Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million.
  • Ensysce Biosciences (NASDAQ:ENSC) shares moved upwards by 84.14% to $0.67. The market value of their outstanding shares is at $5.5 million.
  • Insmed (NASDAQ:INSM) stock rose 24.81% to $123.59. The market value of their outstanding shares is at $21.4 billion. As per the press release, Q2 earnings came out today.
  • Pomdoctor (NASDAQ:POM) stock increased by 23.52% to $0.86. The market value of their outstanding shares is at $83.4 million.
  • Evolent Health (NYSE:EVH) stock increased by 21.1% to $3.73. The market value of their outstanding shares is at $346.4 million. As per the press release, Q2 earnings came out today.
  • Iovance Biotherapeutics (NASDAQ:IOVA) shares moved upwards by 15.0% to $4.99. The company's market cap stands at $1.9 billion. As per the press release, Q2 earnings came out today.

Losers

  • Context Therapeutics (NASDAQ:CNTX) stock fell 29.2% to $0.49 during Thursday's pre-market session. The company's market cap stands at $63.6 million. As per the press release, Q2 earnings came out yesterday.
  • Zhengye Biotechnology (NASDAQ:ZYBT) shares declined by 27.97% to $1.7. The company's market cap stands at $111.8 million.
  • BioVie (NASDAQ:BIVI) shares fell 26.57% to $1.5. The company's market cap stands at $15.3 million.
  • BillionToOne (NASDAQ:BLLN) stock decreased by 25.95% to $111.07. The market value of their outstanding shares is at $6.8 billion. As per the press release, Q3 earnings came out yesterday.
  • SenesTech (NASDAQ:SNES) stock declined by 23.32% to $1.25. The company's market cap stands at $8.6 million. As per the news, the Q2 earnings report came out yesterday.
  • Akebia Therapeutics (NASDAQ:AKBA) stock fell 23.05% to $0.99. The company's market cap stands at $346.0 million. As per the news, the Q2 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.